Tracking multiple sclerosis progression
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study follows people with multiple sclerosis (MS) to see how the disease progresses over time. By tracking your health, researchers hope to learn more about MS and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple sclerosis (MS)
- You are able to read and understand study materials
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with relapsing-remitting multiple sclerosis (RRMS) to find factors that predict disability progression even when they are not having relapses. It may help doctors understand who is at higher risk and guide treatment decisions.
This study follows people with multiple sclerosis over time to learn more about the disease and improve care. If you join, you will help researchers understand MS better, which could lead to better treatments.
This study looks at certain proteins in the blood of people with progressive MS to see if they can predict how the disease will progress. It may help doctors understand and manage the condition better.
This study looks at how certain brain changes relate to disability in people with multiple sclerosis (MS). It aims to see if measuring brain volume loss can help predict disease progression, which might help tailor treatments.
This study follows people with multiple sclerosis over time using a smartphone app and clinic visits. It aims to better understand the disease and improve care.
This study creates a registry for people with multiple sclerosis (MS) to track their health over time. The information gathered may help researchers better understand MS and improve care.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.